Influenza Diagnostics Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Influenza diagnostics include a range of products such as nucleic acid amplification tests, rapid antigen assays, immunofluorescence tests, and point-of-care lateral flow devices used by hospitals, clinics, reference laboratories, and public health agencies worldwide. The market sits at approximately $1 billion in 2025, with estimates from various industry analyses projecting expansion to between $1.6 billion and $2.2 billion over the next decade depending on scope and methodology. Demand is perennial, driven by the annual burden of seasonal influenza, which causes millions of cases of illness globally each year and creates consistent testing needs.

• •Market valued at approximately $1.0 billion in 2025, with projections ranging from $1.6 billion to over $2 billion by the early 2030s
• •Products span molecular tests (RT-PCR, isothermal amplification), rapid antigen assays, immunofluorescence, and point-of-care lateral flow devices
• •End users include hospitals, commercial and hospital laboratories, physician offices, and public health institutions

Recurring seasonal influenza epidemics and periodic pandemic threats sustain strong and recurring demand for diagnostic testing across both developed and developing healthcare systems. Advances in molecular diagnostics, particularly the miniaturization and cost reduction of nucleic acid amplification tests, have made rapid and highly accurate flu detection more accessible outside of centralized laboratories. Growing awareness of the importance of early antiviral treatment, combined with aging demographics and expanding healthcare infrastructure in Asia-Pacific and Latin America, further fuels adoption.

• •Seasonal influenza epidemics and pandemic preparedness continue to drive consistent testing volumes and stockpiling by public health agencies
• •Technological improvements in RT-PCR and isothermal amplification have increased test accuracy while reducing turnaround times
• •Rising healthcare access in emerging markets and growing preference for point-of-care testing are expanding the addressable market

By technology, nucleic acid amplification tests hold the largest share due to their high sensitivity and specificity, while rapid antigen and lateral flow assays dominate the point-of-care segment. The market is also segmented by application into influenza A, influenza B, and combined A/B testing, with multi-pathogen panels gaining traction. Geographically, North America represents the largest regional market, supported by advanced laboratory infrastructure, high healthcare spending, and strong regulatory frameworks, while Asia-Pacific is the fastest-growing region due to rising population, increasing healthcare investment, and greater disease surveillance efforts.

• •Nucleic acid amplification (including RT-PCR and isothermal methods) leads by technology, with lateral flow and immunofluorescence capturing the rapid test segment
• •North America is the dominant regional market, while Asia-Pacific exhibits the strongest growth momentum
• •Multiplex panels that detect influenza alongside other respiratory pathogens are gaining clinical adoption

What are the recent trends and outlook?

The market is moving toward integrated, multiplex respiratory panels that simultaneously test for influenza, RSV, SARS-CoV-2, and other pathogens, reducing the need for sequential testing and improving clinical efficiency. Artificial intelligence and digital connectivity are being incorporated into diagnostic devices for result interpretation and data reporting, supporting public health surveillance. Over the medium term, continued investment in pandemic readiness, coupled with the gradual adoption of at-home and over-the-counter influenza tests, is expected to sustain a compound annual growth rate in the range of 5 to 7 percent through the early 2030s.

• •Multiplex respiratory panels covering influenza alongside RSV, COVID-19, and other pathogens are reshaping testing patterns in clinical labs
• •At-home and over-the-counter influenza tests represent a nascent but growing consumer segment
• •Governments and health agencies are increasing diagnostic stockpiles and surveillance investments, providing underlying demand stability